SHA:601607 Revenue

Shanghai Pharmaceuticals Holding had revenue of 70.83 billion CNY in the quarter ending June 30, 2025, with 2.27% growth. This brings the company's revenue in the last twelve months to 277.43 billion, up 3.86% year-over-year. In the year 2024, Shanghai Pharmaceuticals Holding had annual revenue of 275.25 billion with 5.75% growth.

Revenue (ttm)

277.43B

Revenue Growth

+3.86%

P/S Ratio

0.22

Revenue / Employee

5.54M

Employees

49,402

Market Cap

60.98B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	275.25B	14.96B	5.75%
Dec 31, 2023	260.30B	28.31B	12.21%
Dec 31, 2022	231.98B	16.16B	7.49%
Dec 31, 2021	215.82B	23.92B	12.46%
Dec 31, 2020	191.91B	5.34B	2.86%
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2018	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2017	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2016	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2015	Upgrade Pro	Upgrade Pro	Upgrade Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Huadong Medicine	42.62B
WuXi AppTec	41.90B
Yunnan Baiyao Group Co.,Ltd	40.84B
Shanghai Fosun Pharmaceutical (Group)	40.12B
Shenzhen Mindray Bio-Medical Electronics	32.94B
Jiangsu Hengrui Medicine	30.15B
Zhejiang NHU Company	22.87B
Aier Eye Hospital Group	21.94B

Revenue Rankings

Shanghai Pharmaceuticals Holding News

10 months ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
10 months ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha

More News